Evidence map›Paper›PMID 36943305›Full record

Observational studyInflammatory bowel diseases2024

Assessing the Impact of COVID-19 on IBD Outcomes Among Vulnerable Patient Populations in a Large Metropolitan Center.

Florence-Damilola Odufalu, Justin L Sewell, Vivek Rudrapatna, Ma Somsouk, Uma Mahadevan

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in Inflammatory bowel diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. The impact of COVID-19 on inflammatory bowel disease surgery: a systematic review.Annals of the Royal College of Surgeons of England · 2026
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. COVID-19 Pandemic: Therapeutic Strategies and Vaccines.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Florence-Damilola OdufaluDivision of Gastroenterology and Liver Diseases, Department of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID 0000-0003-3018-7024
Justin L SewellGastroenterology Division, Zuckerberg-Chan San Francisco General Hospital and Trauma Center, University of California, San Francisco, San Francisco, CA, USA.
Vivek RudrapatnaDivision of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Ma SomsoukGastroenterology Division, Zuckerberg-Chan San Francisco General Hospital and Trauma Center, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-6116-3645
Uma MahadevanDivision of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-3067-8061
San Francisco General Hospital · USUniversity of California, San Francisco · USUniversity of Southern California · US

Funding

A data science framework for transforming electronic health records into real-world evidenceK99LM014099 · NLM · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RUDRAPATNA, VIVEK ASHOK · 2023 to 2024
$178k
NLM NIH HHS K99 LM014099
6 · The paper itself

Abstract

backgroundWith the onset of COVID-19, there were rapid changes in healthcare delivery as remote access became the norm. The aim of this study was to determine the impact of changes in healthcare delivery during the COVID-19 pandemic on patients with inflammatory bowel disease (IBD), in both well-resourced and vulnerable populations.

methodsUsing a mixed methods, observational study design, patients receiving IBD care at a university or a safety-net hospital were identified by the electronic health record. Patient demographics, IBD history, and disease activity were acquired from the electronic health record. IBD-related outcomes were compared from the onset of the pandemic in the United States until December 2020 (COVID-19 pandemic year 1) and compared with outcomes in the previous year. A subset of participants provided their perspective on how changes in healthcare delivery and financial stability impacted their IBD through a standardized questionnaire and semi-structured interview.

resultsData from a total of 1449 participants were captured, 1324 at the tertiary care university hospital and 125 at the safety-net hospital. During COVID-19, there was a decrease in healthcare utilization at both sites. Race/ethnicity and primary language were not associated with IBD-related hospitalizations or admissions. Patients that were employed and those with insurance had a higher number of IBD-related emergency department visits at both the university and safety-net hospitals (P = .03 and P = .01, respectively). Patients who did not speak English were more likely to report challenges using technology with telehealth and difficulty contacting IBD providers.

conclusionsFor IBD populations, during COVID-19, in both hospital settings, emergency department visits, hospitalizations, outpatient surgery, and clinic visits were reduced compared with the year prior. Patients with lower socioeconomic status and limited English proficiency reported facing more challenges with changes to healthcare delivery, healthcare access, and conveying changes in IBD activity. These results highlight the need for payors and providers to specifically attend to those populations most susceptible to these systemic and lasting changes in care delivery and promote greater equity in healthcare.

Indexed as

COVID-19Inflammatory Bowel DiseasesDelivery of Health CareHumansPandemicsUnited StatesVulnerable PopulationsCOVID-19IBD outcomessocial disparities

Identifiers

PMID36943305
PMCPMC11502948
OpenAlexW4328049403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.